Moderna Q2 EPS $(3.62) Beats $(3.84) Estimate, Sales $344.00M Beat $290.74M Estimate
Portfolio Pulse from Benzinga Newsdesk
Moderna reported Q2 earnings per share (EPS) of $(3.62), beating the analyst consensus estimate of $(3.84) by 5.73%. This is a 169.08% decrease from the same period last year. The company also reported quarterly sales of $344.00 million, surpassing the analyst consensus estimate of $290.74 million by 18.32%. This represents a 92.76% decrease from the same period last year.
August 04, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Moderna's Q2 results beat analyst estimates for both EPS and sales. However, both figures represent significant decreases from the same period last year.
While Moderna beat analyst estimates for Q2, the significant year-over-year decreases in both EPS and sales could potentially concern investors. The impact on the stock price is uncertain as the positive of beating estimates is offset by the negative of the YoY decreases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100